SCA
AQST icon

Snowden Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Snowden Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45K Buy
10,848
+75
+0.7% +$304 ﹤0.01% 1270
2025
Q4 		$69.6K Buy
+10,773
New +$67.1K ﹤0.01% 1255

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Snowden Capital Advisors's AQST Position: Q1 2026 in Review

Snowden Capital Advisors increased its Aquestive Therapeutics (AQST) stake by 0.7% in Q1 2026, buying an estimated $304 and bringing the position to 10,848 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Snowden Capital Advisors first reported a position in AQST in Q4 2025 and has held it in 2 quarters since. The position peaked at $69.6K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Snowden Capital Advisors held 10,848 shares of Aquestive Therapeutics worth $45K as of Q1 2026.
  • Snowden Capital Advisors bought 75 Aquestive Therapeutics shares in Q1 2026, an estimated $304.
  • Aquestive Therapeutics made up ﹤0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1270 holding.
  • Snowden Capital Advisors first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Snowden Capital Advisors's Aquestive Therapeutics position peaked at $69.6K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.